PGP9.5 (Gracile Axonal Dystrophy, Neuron Cytoplasmic Protein 9.5, Park5, Parkinson Disease 5, PGP95, Protein Gene Product 9.5, Ubiquitin Carboxyl-terminal Esterase L1, Ubiquitin Carboxyl-terminal Hydrolase Isozyme L1, Ubiquitin Thioesterase L1, Ubiquitin Thiolesterase L1, UchL1) (APC)

This MAb reacts with a protein of 20-30kD, identified as PGP9.5, also known as ubiquitin carboxyl-terminal hydrolase-1 (UchL1). Initially, PGP9.5 expression in normal tissues was reported in neurons and neuroendocrine cells but later it was found in distal renal tubular epithelium, spermatogonia, Leydig cells, oocytes, melanocytes, prostatic secretory epithelium, ejaculatory duct cells, epididymis, mammary epithelial cells, Merkel cells, and dermal fibroblasts. Furthermore, immunostaining for PGP9.5 has been shown in a wide variety of mesenchymal neoplasms as well. A mutation in PGP9.5 gene is believed to cause a form of Parkinson's disease.

Applications:
Suitable for use in Immunofluorescence, FLISA, Western Blot, Immunohistochemistry. Other applications not tested.

Recommended Dilution:
Western Blot: 0.5-1ug/ml
Immunofluorescence: 1-2ug/ml
Immunohistochemistry: Frozen only
Optimal dilution for a specific application should be determined.

Positive Control:
Cerebellum

Storage and Stability:
May be stored at 4°C before opening. DO NOT FREEZE! Stable at 4°C as an undiluted liquid. Dilute only prior to immediate use. Stable for 12 months after receipt. For maximum recovery of product, centrifuge the original vial prior to removing the cap. Further dilutions can be made in assay buffer. APC is light sensitive.

Note: Applications are based on unconjugated antibody.